QL1005
aka GLP-1/GDF15 dual agonist fusion protein
Class Dual incretin-GDF15 fusion protein / first-in-class muscle-sparing anorexigen
Status Pre-clinical / Early Phase 1 (2026); Qilu Pharmaceutical (Jinan, China)
TL;DR
QL1005 fuses a GLP-1 variant to a GDF15 analogue via albumin-binding C-18 fatty di-acid acylation, giving ~41-hour NHP half-life (once-weekly SubQ). The key differentiator: GDF15 drives fat oxidation via the GFRAL-RET brainstem axis and sympathetic-adrenergic ATGL lipolysis — muscle is not targeted. In DIO mice: ~35% body weight reduction (vs. GLP-1 mono ~20%), weight loss = predominantly fat, lean preserved. Human DEXA data awaited — this is the primary validation endpoint. The GDF15 monotherapy translational failure (LY3463251: 3% weight loss; MBL949: negligible) means QL1005’s GLP-1 primer hypothesis needs human confirmation.
Why it matters for Vitals
QL1005 is the first GLP-1 space compound that theoretically solves the lean mass problem pharmacologically — without requiring a separate anabolic agent. If human DEXA data confirms muscle preservation at scale, this becomes a primary body-composition anchor for aging and cardiac patients. The dual-circuit design (GLP-1 + GDF15) means it should retain efficacy in GLP-1-resistant or leptin-resistant phenotypes. GDF15’s anti-inflammatory effect (macrophage marker downregulation) positions it for MASH/CKM syndrome use beyond weight loss alone.
Key Facts
| Mechanism | GLP-1R agonism (satiety, insulin secretion, gastric delay) + GFRAL-RET agonism (sympathetic-adrenergic ATGL lipolysis, hedonic hunger suppression) |
| Muscle sparing | GFRAL-β-adrenergic axis targets adipose ATGL; muscle not a substrate; lean mass preserved in DIO mice and NHP |
| Preclinical weight loss | ~35% in DIO mice (significantly > GLP-1 mono comparators) |
| NHP half-life | ~41 hours (comparable to semaglutide in same species); weekly dosing |
| GLP-1:GDF15 balance | Pathway-balanced confirmed: knocking out either axis reduces efficacy ~50% |
| GI tolerability | Exceptionally good in NHP; pathway-balanced design stays below emetic threshold |
| Key risk | Human DEXA data not yet available; GDF15 monotherapy has failed in humans (must confirm GLP-1 primer hypothesis) |
| Evidence | DIO mice; cynomolgus monkey PK/PD; CIN-109 (pure GDF15) Phase 1 human proof-of-concept |
Dual Mechanism
GLP-1R Axis (familiar)
- Hindbrain/hypothalamus → satiety, appetite suppression (hedonic + homeostatic)
- Pancreas → glucose-dependent insulin secretion, glucagon suppression
- Delays gastric emptying → blunts postprandial glucose
- Limitation: Adaptive mechanisms cause plateau (ghrelin surge, metabolic rate drop)
GFRAL-RET Axis (the differentiator)
GDF15 signals exclusively through GFRAL + RET co-receptor complex, expressed in:
- Area postrema (circumventricular — no BBB barrier; QL1005 accesses easily)
- Nucleus tractus solitarius (NTS)
Central: Profound, sustained hedonic hunger suppression — operates completely independently of leptin and GLP-1; retains activity in GLP-1R deficiency or leptin resistance.
Peripheral — the muscle-sparing mechanism:
- GFRAL activation → descending sympathetic efferent → GFRAL-β-adrenergic axis
- Beta-adrenergic stimulation of adipose tissue → upregulates adipose triglyceride lipase (ATGL)
- Targeted lipolysis of visceral and subcutaneous fat → fatty acid oxidation
- Chemical sympathectomy or ATGL deficiency: near-total resistance to GDF15 lipolytic effects
- Muscle is NOT a substrate — sympathetic signal goes to fat, not muscle
Anti-inflammatory (bonus):
- Downregulates macrophage infiltration markers (F4/80, CD11b, CD11c) in liver and adipose
- Resolves chronic low-grade inflammation driving insulin resistance
The GDF15 Translational Problem
Previous GDF15 monotherapies failed in humans despite impressive animal data:
| Agent | Company | Outcome |
|---|---|---|
| LY3463251 | Eli Lilly | Phase 1: only 3% weight loss over 12 weeks; doses caused severe nausea → unusable therapeutic window |
| MBL949 | Novartis | Phase 1/2: minimal to negligible weight reduction after 14 weeks; halted |
CIN-109 (CinFina/Janssen, pure GDF15): Phase 1: 50% decrease in food intake, 3.7% weight loss in 2 months, weight loss = almost entirely fat, lean mass increased, zero serious adverse events. Proof that the pathway works in humans — but needs the GLP-1 synergy to unlock full efficacy.
QL1005’s proposed fix: GLP-1 component provides baseline metabolic efficacy and sensitizes the system; GDF15 adds a second, non-redundant circuit. Co-administration data (GDF15 + semaglutide) supports this: substantially greater food intake suppression than either alone without worsening nausea.
Body Composition vs. Retatrutide
| Drug | Mechanism | Clinical weight loss | Muscle impact |
|---|---|---|---|
| Semaglutide | GLP-1 mono | ~15% | ~40% of loss is lean |
| Tirzepatide | GLP-1 + GIP | ~20–22.5% | ~25% of loss is lean |
| Retatrutide | GLP-1 + GIP + GCGR | ~28.7% | Still significant lean loss |
| QL1005 | GLP-1 + GDF15 | ~35% (mice); pending human) | Predominantly fat; lean preserved |
vs. Retatrutide: Retatrutide wins on brute-force thermogenesis and hepatic fat clearance. QL1005 wins on body composition quality, cardiovascular safety (no GCGR-driven tachycardia), and theoretically better lean mass outcomes. Different patients: QL1005 better for aging populations, cardiac vulnerability, or those prioritizing the leanest possible body composition.
vs. Tirzepatide: GDF15 operates on a circuit tirzepatide cannot access. For tirzepatide non-responders or those who plateau → QL1005 is the logical step-up.
Stacks
| Stack | Rationale |
|---|---|
| + XW4475 | QL1005 spares muscle via GDF15/ATGL; XW4475 builds it via CRF2/mTOR → potentially the optimal lean recomposition stack when both are available (~2027–2028) |
| + SLU-PP-332 | GDF15 drives fat oxidation via sympathetic/ATGL; SLU-PP-332 drives it via ERR/mitochondrial biogenesis — different mechanisms, potentially additive |
| + BPC-157 | BPC-157 angiogenesis supports vascular supply for preserved/growing muscle; low conflict |
| + PCC1 | QL1005 removes adipose mass + resolves macrophage inflammation; PCC1 clears senescent cells driving residual SASP — sequential logic |
Do not stack QL1005 + Retatrutide as co-primary anchors — significant GLP-1R overlap. Choose one as the anchor agent.
Risks and Uncertainty
- Human DEXA data pending — muscle preservation in mice/NHP may not fully translate
- GDF15 translational risk is real — LY3463251 and MBL949 failures show the path is uncertain
- CIN-109 human data is indirect evidence only — not a guarantee of QL1005 efficacy
- No human tolerability data beyond NHP
- Phase 1/2 ongoing in 2026 — out-licensing to Western pharma likely before market
Links
- GLP-1 GIP Glucagon — GLP-1R/GFRAL overlap; GDF15 adds the missing axis
- Retatrutide — body composition anchor comparison; different GLP-1R saturation approach
- XW4475 — muscle-building stack pairing
- SLU-PP-332 — complementary fat oxidation
- Peptides MOC
Source: Zhang et al. Cell Metabolism 2023 · NHP pharmacokinetic studies · CIN-109 Phase 1 data · Qilu pipeline reports · Gemini Deep Research 2026-03-12